Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1043 clinical trials
VitaFlow II Transcatheter Aortic Valve System Pre-market Trial

This is a pre-market clinical investigation aiming to evaluate the safety and effectiveness of Microport CardioFlow VitaFlow II Transcatheter Aortic Valve System for the treatment of severe aortic stenosis.

stenosis
aortic stenosis
aortic valve replacement
transcatheter aortic valve implantation
  • 0 views
  • 19 Feb, 2024
Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI

Prospective data for self-expanding devices are required to compare the extent of paravalvular leakage as a result of device design. Grading paravalvular leakage after TAVI is difficult. Echocardiography and angiography systematically underestimate paravalvular leakage (PVL) as compared to cardiac MRI.

blood transfusion
symptomatic aortic stenosis
regurgitation
angina
renal failure
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective conversion treatment for HCC, and preoperative treatment with lenvatinib can improve resectability in …

  • 0 views
  • 19 Feb, 2024
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus

A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and intravenous immunoglobulins (IVIG) has shown to be effective for refractory pemphigus cases …

immunosuppressants
autoimmune disease
intravenous immunoglobulin
igiv
rituximab
  • 0 views
  • 19 Feb, 2024
Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

amlodipine 5 mg
moxonidine
ace inhibitor
amlodipine
body mass index
  • 0 views
  • 19 Feb, 2024
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia.

contraceptive use
rituximab
lymphoma
refractory b-cell non-hodgkin lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 19 Feb, 2024
Carfilzomib Daratumumab Lenalidomide and Dexamethasone as First Line Treatment in Multiple Myeloma

Carfilzomib in combination with lenalidomide, daratumumab and dexamethasone (KRDd) can induce profound clinical responses. The investigators want to observe the effectiveness of the quadruple therapy of carfilzomib, lenalidomide, daratumumab and dexamethasone on patients receiving 8 cycles of KRDd with autologous stem cell transplantation versus patients with 8 cycles of KRDd …

bone lesion
bone marrow procedure
bone marrow plasma cells
cell transplantation
calcium
  • 0 views
  • 19 Feb, 2024
Mobile App as a Guide to Exercises for Patients With Chronic Stroke

Introduction: Stroke continues to be one of the leading causes of disability in the Spanish adult population with the presentation of impairments such as alteration of mobility and a consequent reduction in quality of life. These sequelae, generally chronic, generates a significant expense and saturation of social and health services.

hemiparesis
stroke
physical rehabilitation
hemiplegia
hemiplegia or hemiparesis
  • 0 views
  • 19 Feb, 2024
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.

SARS
hydroxychloroquine
covid-19
acute respiratory syndrome (sars)
  • 0 views
  • 19 Feb, 2024
Brief Title: Study of BGB-10188 as Monotherapy and in Combination With Zanubrutinib and Tislelizumab

The purpose of this study is to determine the maximum tolerated dose (MTD), recommended Phase 2 dose(RP2D),safety & tolerability of BGB-10188: as monotherapy in participants with mature B-cell malignancies; oin combination with zanubrutinib in participants with relapse/refractory follicular lymphoma (R/R FL), mantle cell lymphoma (MCL) or diffuse large B-cell lymphoma …

nasopharyngeal carcinoma
endometrial carcinoma
lymphoma
cancer, hepatocellular
melanoma
  • 0 views
  • 19 Feb, 2024